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Anya Rothenbuhler, Agnès Linglart and Pierre Bougnères*Abstract
Background: When given during the course of puberty, anastrozole (A), an aromatase inhibitor, has been shown
to increase the predicted adult height (PAH) of GH-deficient (GHD) boys treated with recombinant human growth
hormone (rhGH). Our study questioned whether this treatment could retain some of its effects in non-GHD
adolescent boys if started only at the very end of puberty, a time when rhGH treatment is denied to short adolescents
who have almost reached their final height.
Objective: To explore the effect on adult height of a combination of rhGH and A, compared with rhGH alone, at the
end of puberty in boys with idiopatic short stature (ISS).
Methods: A prospective randomized study comparing rhGH + A and rhGH was conducted in 24 healthy adolescent
boys aged 15.2 ± 1.2 yrs with serum testosterone at adult levels and a faltering growth velocity <3.5 cm/yr leading
to a predicted adult height (PAH) <2.5 SDS. Treatments were stopped when growth velocity became <10 mm in
6 months or when height was close to 170 cm. A historical group of ISS adolescents (N = 17) matched for puberty
and growth was used for comparison.
Results: IGF1 levels remained within normal limits in all treated patients. Mean treatment duration was 19 months
in the rhGH + A group and 11.5 months in the rhGH group (P = 6.10−4). Adult height reached 168.4 ± 2.6 cm in
the rhGH + A group and 164.2 ± 5.6 cm in the rhGH group (P < 0.02). Adult height was 160.1 ± 2.8 cm in the
historical controls.
Conclusion: A combination of rhGH and A, started at the very end of puberty, seems to allow boys with ISS to
reach a greater adult height than rhGH alone. Larger trials are needed to confirm this preliminary observation.
Keywords: Idiopathic short stature, Anastrozole, Growth hormone, Short children, End of pubertyIntroduction
Idiopathic short stature (ISS) describes a heterogeneous
group of children of unknown etiology [1-4] who become
adults of short stature [5-18]. Based on general considera-
tions on the tolerability of short stature by adults [19-30],
and on the limited height benefit that is considered to
result from years of a costly treatment whose long term
safety has been questioned (see Discussion) [31-37], the
use of recombinant human growth hormone (rhGH) to* Correspondence: pierre.bougneres@inserm.fr
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unless otherwise stated.increase the height of healthy children with ISS remains
debated. The prerequisites for the use of rhGH in ISS
set by the FDA are that other diagnoses are excluded,
that the presenting height is < −2.25 SDS for age and
sex, and that adult stature is expected to be < −2.0 SDS
[2]. Several reviews of studies on treatment with rhGH
in ISS [1-3,38-40] concluded that a mean gain in pre-
dicted adult height (PAH) of ~5-7 cm can be expected
following an average of 5.4 years of treatment. More
meaningful information comes from studies that have
provided adult height values [12-18,41-44]. In fact, the
different studies showed different rhGH-induced heightentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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discussed in the study by Sotos and al [41]. The poten-
tial growth promoting effect of starting rhGH adminis-
tration at the very end of puberty, months to years after
height peak velocity is passed, has not been explored
yet. At his particular moment, the fusion of epiphyseal
plates of the long bones governs the tempo of growth
deceleration; when growth velocity falls under 15 mm
per 6 months, cessation of growth is expected to occur
within the next two years [53-56].
The use of aromatase inhibitors for promoting growth
has been recently reviewed [57-63] and a debate has
started in the pediatric endocrinology community regard-
ing the benefit/risk ratio of these drugs [64,65]. In non-
growth hormone deficient (GHD) boys with ISS and/or
delayed puberty, aromatase inhibitors effectively delay
bone maturation and thereby increase PAH [66-69]. In a
Finnish study, 23 boys aged 15.1 years with delayed pu-
berty were randomly allocated to 1 year of letrozole or pla-
cebo. Both groups also received testosterone injections for
6 months and were evaluated 18 months after initiation of
therapy [66]. A third, nonrandomized group received no
treatment. PAH increased by 5.1 cm with letrozole vs
0.3 cm with placebo. The nonrandomized, untreated con-
trols gained 2 cm. In a follow-up study [68], the near-adult
height of the letrozole-treated group was 6.9 cm more
than the placebo group, positive results that might have
been affected by a selection bias at start of treatment [57].
In another 2-year randomized study of 91 Iranian boys
with a constitutional delay of growth and puberty, letro-
zole increased PAH more than placebo [69]. In a Finnish
study, 30 boys with ISS aged 9.0–14.5 years were ran-
domly allocated to receive either letrozole or placebo for
2 years [67]. Most participants (81% and 93%, respectively)
had not entered puberty at the start of the study, and 44%
after 2 years. Height at start was < −2 SDS and mean bone
age < 14 years. Letrozole-treated boys showed growth vel-
ocities similar to those receiving placebo, and again bone
age advanced less with letrozole therapy, thus the PAH
increased by 5.9 cm However, when reevaluating the
results in 23/30 six years after starting the study, the dif-
ference in PAH was no longer statistically significant
(166.5 cm in letrozole-treated versus 162.4 cm in placebo-
treated) [70]. Adult height data are not available for these
trials [57].
The efficacy of anastrozole co-treatment with rhGH
has been investigated in GHD boys in two studies from
the same US center [71,72]. An open-label pilot study
on 20 patients treated for 1 year did not show an effect
on PAH [71]. In a later study, 52 male adolescents treated
with rhGH for GH deficiency were randomly allocated to
co-treatment with A or placebo for 1–3 years [72]. At
entry, serum testosterone was in a 1–3 ng/ml range. PAH
increased in the A-treated group by 6.7 cm after 3 years,whereas only 1 cm of PAH gain was observed in the pla-
cebo group [72]. The decrease in growth velocity during
the course of the study was greater in the placebo group
than in the A group at 36 months [61,72] No adult height
data are available to date.
These results paved the way for testing the combin-
ation of rhGH +A in adolescents with ISS who are fin-
ishing their growth. Indeed, we were not aware of any
trial having tested the combination of rhGH and A in
ISS during the late stage of near-ending growth, likely
because adolescents, families, and most pediatric endocri-
nologists believe it would be too late for rhGH to allow a
significant gain in stature. The current pilot trial ques-
tioned this belief in a sample of adolescents with predicted
adult short stature. When their growth velocity drops,
boys of short stature realize that they will not be able to




Based on previous results with aromatase inhibitors, a min-
imal sample size was calculated to allow detecting a 6 cm
increase in final height by adding A to rhGH with an alpha
of 0.05 and a power of 0.80. We included 24 adolescents
who consulted us between March 2004 and September
2009. They were selected on the following inclusion cri-
teria: a complete or near complete sexual maturation (tes-
tes volume >12 ml and adult testosterone levels), a reliable
series of height measurements over puberty showing a de-
celerating growth velocity equal or less than 3.5 cm/yr dur-
ing the preceding 6 months, leading to a PAH < −2.5 SDS
(see our model for calculation in lower section). We chose
this height because a well-conducted quality-of-life (QOL)
study set 160 cm as the threshold for observing a nega-
tive impact of short stature on male adults [19]. Al-
though only a fraction of these adolescents fulfilled the
strict definition of ISS at time of entry (because their
height was not < −2SDS), they would have fulfilled the
definition at adult ages, given the PAH. Although a mix
of short stature and mildly advanced puberty would
seem a more accurate definition for approximately half
of the adolescent boys, we used the generic term “ISS” to
define their category for simplification. GH deficiency was
excluded by a stimulation test with a GH peak value
superior to 15 ng/ml. This cut-off threshold was chosen
instead of the usual 5–10 ng/ml value to adjust to the age
of the participants and ensure that no studied adolescent
had any degree of GH deficiency. Subtle forms of dys-
chondrosteosis or other chondrodysplasia were excluded
by radiographs of the forearm, spine, hand, pelvis and leg.
TSH levels were normal. All adolescents were healthy.
The growth trajectory could be modeled in the adoles-
cents from their “Carnet de Santé”, a national pediatric
Figure 1 Pubertal growth and response to rhGH + A treatment in a representative adolescent. Height of a patient showing actual growth
(continuous dotted line), age at take off (ATO), age at peak growth velocity (APV), age at rhGH onset, predicted growth trajectory, response to GH
administration and final height. HG = height gain. HI = height increase.
Table 1 Characteristics of the 24 adolescent males at
onset of rhGH or rhGH + Anastrazole administration and
historical controls




N 12 12 17
Father’s height
cm 168.5 ± 4.9 168.9 ± 3.6 169.2 ± 4.1
SDS - 1.2 ± 0.8 - 1.1 ± 0.6 −1.1 ± 0.8
Mother’s height
cm 157.8 ± 5.8 156.4 ± 6 157.9 ± 5
SDS - 1.2 ± 1 - 1.2 ± 1.1 −1.2 ± 1
Birth length (cm) 48.3 ± 1 48.2 ± 1.2 48.4 ± 1.2
Age (yrs) 15.2 ± 1.1 15.2 ± 0.8 15.1 ± 0.8
Height
cm 156.3 ± 2.9 155.9 ± 4 156.1 ± 3.5
SDS - 1.70 ± 1 - 1.70 ± 0.7 −1.67 ± 0.8
Weight (kg) 49.8 ± 4 48 ± 6 49.9 ± 4
Testes volume (ml) 22.4 ± 8 22.2 ± 5 22 ± 5
Serum testosterone
(ng/ml)
5.5 ± 0.9 5.6 ± 0.9 5.5 ± 0.8
Bone age at hand (yrs) 14.6 ± 0.6 14.5 ± 0.8 14.6 ± 0.7
Knee score* 2.8 ± 0.7 2.8 ± 0.4 2.7 ± 0.4 (N = 10)
IGF1 (SDS) - 0.5 ± 0.4 - 0.3 ± 0.6 −0.4 ± 0.6 (N = 10)
We observed no significant differences between the groups. Values are
expressed as mean ± SD.
*see Methods.
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pediatricians or general practitioners during the period
of growth [73]. The pubertal growth spurt trajectory was
approximated using the height and age at the two inflec-
tion points that mark the onset of acceleration (take-off )
and starting deceleration (peak growth velocity), respect-
ively (Figure 1 and Tables 1 and 2) [53,54]. Height mea-
surements were performed independently at onset and
end of visit, using a stadiometer with 0.11% precision
(SD/mean). Testes volume was evaluated with a direct
measurement of their major and minor axes and calcula-
tion of the corresponding ellipsoid.
The same investigators (GK, AR, PB) evaluated bone
age at the hand independently according to Greulich and
Pyle [74] and the degree of closing of the femoral inferior
and tibial superior growth plates according to O'Connor
and Roche [75,76] then averaged their estimations. These
evaluations were blind to treatment allocation.
The parents were informed by written material about
the uncertainties of rhGH or A benefits at this age, about
the results of the rhGH and A safety studies, and knew
the position of the national agencies before giving their
written informed consent to the trial according to the
French rules of bioethics.
A group of historical controls was formed with 17 un-
treated adolescent males with ISS matched for testoster-
one, bone age and growth velocity (3 were older brothers
of adolescents from the rhGH group, 3 from the rhGH+A
group). These subjects have consulted our center for ISS
without a strong enough motivation for considering GH
treatment. We used the data collected from their Carnet
de santé and final height to model their growth trajectory.
Knee score was available in only 9 of them. Other missing
Table 2 Characteristics of the growth curve of the 24
adolescent males at onset of rhGH or rhGH + Anastrazole
administration




N 12 12 17
Age at take-off of growth (yrs) 12.3 ± 1.2 12.3 ± 0.9 12.2 ± 1.5
Height at take-off of growth
cm 139.7 ± 4 139.7 ± 3 140 ± 5
SDS - 1.2 ± 0.7 - 1.5 ± 0.9 −1.2 ± 0.9
Age at peak velocity (yrs) 14.3 ± 1 14.2 ± 0.7 14.3 ± 1.2
Height at peak velocity (HPV)
cm 154.1 ± 4 153.6 ± 5 154 ± 6
SDS - 1.3 ± 1 - 1.1 ± 0.8 −1.3 ± 1.1
Time interval between PGV
and GH onset (mo)*a
0.9 ± 0.6 1 ± 0.5 1 ± 0.7**
Growth velocity between PGV
and GH onset
cm/yr 2 ± 1 2.3 ± 0.7 2.2 ± 0.8**
SDS - 2.6 ± 1.4 - 3 ± 1.7 −2.8 ± 1.9**
We observed no significant differences between the groups. Values are
expressed as mean ± SD.
a*see Methods.
**mean age at GH onset in the GH treated adolescents was used to calculate
corresponding values for time interval and growth velocity in the
historical controls.
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end of adolescence and serial IGF1 measurements
Randomization and treatment protocol
The randomization procedure was chosen to allow the
parallel treatment of participating children under each
regimen. Initially, our three-arm protocol randomly allo-
cated 1 subject per group of 3 adolescents (allocation was
drawn at pre-inclusion in the trial) to rhGH, rhGH+A, or
no treatment. After three years and inclusion of six groups
(N = 18), a primary refusal had occurred in 4/6 subjects in
the untreated group, who sought rhGH treatment in other
centers. Therefore we could not maintain a reasonable
rate of accrual for the recruitment of the untreated arm,
thus we switched our randomization process to allocation
of 2 subjects within groups of 4 to rhGH or rhGH+A
treatment. We stopped the inclusions after a total of 12
subjects had been included in each treatment arm.
rhGH was given at an initial dose of approximately
0.07 mg/kg.d then adjusted to growth velocity while main-
taining serum IGF1 level close to +1SDS. Anastrozole (A)
was given at a daily dose of 2 mg. The doses of both rhGH
and A were deliberately chosen to be high, based on the
short expected duration of trial, in order to maximize the
therapeutic effects.
Patients were seen every 3 months until near-end of
growth. Treatment was stopped when growth velocityunder rhGH treatment was < 10 mm over 6 months
(N = 18) or when the adolescent has reached a height
near 170 cm (N = 6).
At each consultation, parents and adolescents were
asked to fill out a questionnaire that listed known sec-
ondary effects of A, including mood changes and neuro-
psychic symptoms (depression, nervousness, dizziness,
insomnia, weakness), hot flashes, digestive symptoms
(stomach pain, nausea, loss of appetite, constipation,
diarrhea, vomiting), skin (rash, acne), joint symptoms
(arthralgia, arthritis), back pain, muscle pain, headaches.
Biological parameters
Serum IGF1 levels were measured between 7 and 11 am,
12–16 hours after the previous evening rhGH injection.
Values at 6, 9, 12, 15, 18 and 24 months were used for
monitoring rhGH treatment and were averaged to calculate
individual IGF1 means during rhGH administration Serum
IGF1 was measured by immunoradiometric assay after
ethanol-acid extraction using DSL-5600 Active reagents
(Diagnostic Systems Laboratories, Webster, TX). IGF1 SDS
calculations were provided by DSL as reported [77]. Intra-
and interseries coefficients of variation were 1.5 and
3.7% at 260 ng/ml, and 2.5 and 3.9% at 760 ng/ml. The
sensitivity was 4 ng/ml. FSH and LH were measured as
reported by a time-resolved fluorometric assay using
Delfia reagents (Perkin Elmer Life Sciences, Courtaboeuf,
France). Sensitivity for both assays was 0.01 IU/liter.
Serum testosterone was measured every six months with a
direct RIA (CisBio International, Gif sur Yvette, France).
Sensitivity was 0.01 ng/ml (0.05 nmol/liter).
Growth model, calculation and statistics
As pointed by Garn et al. [78] the bone age evaluated at
the hand (wrist and phalanges) at the end of puberty
does not predict the complete epiphyseal union of long
bones of the leg, thus we did not use the Bayley Pinneau
method based on the hand. Instead, we modeled the
deceleration of growth velocity in each adolescent to be
able to extrapolate adult height, using the age (t) and
height (h) of each subject accurately measured during
the deceleration period, we modeled. We considered that
growth velocity thereafter slows uniformly and is termi-
nated within 2 years from the peak growth velocity. The
slope p of the curve is approximated from the recorded
values at peak growth velocity (t1,h1) and at rhGH onset
(t2,h2) as p = (h2-h1)/(t2-t1)). The derivative between
rhGH onset and final h is f'(t) = p - p/(tfin-t2) * (t-t2).
Integral is f(t) = p*t - p/(tfin-t2)* (1/2*t
2 - t2*t) + K. When
t = t2, f(t2) = h2, then k = h2 - {p*t2 + p/2(tfin-t2)*t2
2}.
The growth curve is thus made of real values between
t1 and t2, then between t2 and tfin of the function that
we determined, then becomes null 2 years after peak
growth velocity time. We tested the potential benefit of
Table 3 Main parameters and effects of of rhGH or rhGH +
Anastrazole administration in the 24 adolescent males




GH dosage (mg/k.d) 0.073 ± 0.09 0.076 ± 0.01 NS
Duration of GH administration (mo) 11.5 ± 5 19 ± 5.9 0.02
Age at end of GH (yrs) 16.2 ± 1.1 16.8 ± 0.7 0.08
Mean IGF1 (SDS) 0.55 ± 0.3 0.65 ± 0.6 NS
Delta IGF1 (SDS)* 1.02 ± 0.3 0.97 ± 0.5 NS
Predicted height**
cm 158.2 ± 2.9 157.9 ± 3.8 NS
SDS - 2.84 ± 0.5 - 2.9 ± 0.6 NS
Final height
cm 164.2 ± 5.6 168.4 ± 2.6 0.02
SDS - 1.8 ± 0.9 - 1.1 ± 0.4 0.02
Growth velocity Year 1 (cm/yr) 4.9 ± 4 6.7 ± 2.8 0.18
Growth velocity Year 2 (cm/yr) 1.2 ± 0.5 3.6 ± 2.7 0.008
Height increase from GH onset
(HtG1) (cm)
7.8 ± 5 12.7 ± 5.6 0.02
Height gain vs PAH (HtG2) (cm) 5.9 ± 4.5 10.5 ± 5.2 0.02
Values are expressed as mean ± SD.
*Mean IGF1 during GH-IGF1 at onset of GH.
**see Methods/Calculation.
Figure 2 Correlation between the duration of rhGH administration
and height increase. Black dots figure the children treated with
rhGH alone, empty circles those treated with rhGH and anastrozole.
The height increase up to final height is closely correlated with the
duration of rhGH administration according to the equation Y = 70X +
0.025 (R = 0.82, P = 2×10−7).
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dent’s t test and the chi-square test.
Results
The two randomized groups of adolescent boys had
comparable characteristics as shown in Table 1 including
the pubertal growth spurt trajectory shown in Table 2.
None of the studied adolescents had a constitutional delay
of puberty, 18/22 had followed a normal maturation pat-
tern. At inclusion, four could be considered early matur-
ing boys according to Sandberg and al [23], with ages at
take-off growth 10–12 yrs, age at peak growth velocity
12.5-13 yrs and full sexual development achieved at age
13–13.5 yrs. rhGH treatment was initiated at 15.2 ±
1.2 yrs in the rhGH group and 15.2 ± 0.8 yrs in the
rhGH + A group.
The main parameters of the treatment and height evolu-
tion are shown in Table 3. A representative growth chart
(Figure 1) illustrates what we observed in many children.
The 12 adolescents of the rhGH group stopped growing
after 11.5 ± 5 months, while those in the rhGH+A group
kept growing for 19 ± 6 months (P = 6.10−4), leading to
termination of treatment at 16.2 ± 1.1 yrs in the rhGH
group and 16.8 ± 0.6 yrs in the rhGH+A group. During
the treatment period, all patients maintained their IGF1
level within 0–1.5 SDS (average 0.60 ± 0.45 SDS). Only 5
of the 66 total IGF1 measures exceeded +2SD on one oc-
casion and not one IGF1 value ever exceeded +2.5 SDS.
Adult height was 164.2 ± 5.6 cm in the rhGH alone group
and 168.4 ± 2.6 cm in the rhGH+A group (P = 0.019). The
difference between adult height and height at rhGH onset
was 7.8 ± 5 cm in the rhGH group, and 12.7 ± 5.6 cm in
the rhGH+A group (P = 0.023). Individual height increase
was variable. For example, 4/12 (33%) adolescents in the
rhGH group showed an increase of height <3 cm (mean
1.85 cm, range 0.6 to 2.6 cm) vs 0% in the rhGH+A
group, despite comparable knee score and growth velocity
at onset of treatment (P = 0.046).
We found that the increase in height correlated closely
with the duration of rhGH treatment (R = −0.82, P = 0.01)
(Figure 2). The magnitude of the height gain was also
negatively correlated with the knee score when both
groups were merged (R = −0.59, P = 0.002), not with bone
age at the hand. In fact, the correlation of height increase
with knee score was strong in the adolescents treated with
rhGH alone (R = −0.86, P = 0.01). We also found that the
persisting growth velocity at the time of rhGH onset was
another predictor of height increase (R = 0.70, P = 0.0015).
The failure to respond to rhGH was associated with a
higher knee score and a minimal growth velocity at time
of rhGH onset.
We found no significant correlation of height increase
with baseline IGF1 or with the increase in IGF1 in response
to rhGH, nor with other studied parameters in either group
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At entry in the trial, PAH calculated with our equation
is 158.2 ± 2.9 cm in the rhGH group and 157.9 ± 3.7 cm
in the rhGH+A group. Therefore the difference between
reached adult height and PAH before treatment was 5.9 ±
4.5 cm in the rhGH group and 10.5 ± 5.1 cm in the
rhGH + A group (P = 0.019). This difference had the
expected high degree of correlation with the increase in
height from the onset of rhGH administration (Y =
1.0X + 1.8; R = 0.97, P = 5.10−9), and the same predictors
(Additional file 1).
The historical controls were comparable to the partici-
pants for age, bone age at the hand and epiphyseal closure
at knee, testes volume and testosterone levels at entry into
the trial (Tables 1 and 2). They reached a mean final adult
height of 160.1 ± 2.8 cm (−2.5 SDS), lower than that of
adolescents treated with rhGH (P < 0.05) or with rhGH+A
(P < 0.0001) (Table 3). This statistical difference should
however be considered questionable given the non-
randomized nature of the untreated group. True adult
height was close to PAH (calculated to be 160.3 ± 5 cm),
which validates our predictive equation.
We detected no significant secondary effects of rhGH or
A during the short observation period (Additional file 2).
Lipid values, testosterone and gonadotropin values during
the rhGH+A treatment are presented at Additional file 3.
Discussion
rhGH studies on ISS have focused on childhood or on
the beginning of puberty [2,7,12-18,20,33,37-52], with the
belief that a younger age favors rhGH effects [37]. Growth-
promoting effects of aromatase inhibitors, employed alone
[66-70,79,80] or in conjunction with rhGH [71,72], have
only been explored in pre-pubertal adolescents with ISS
[67,70,79] or in adolescents with constitutional delay of
puberty [66,68-70] or GH deficiency [71,72]. Despite an ex-
tensive Pubmed search, we were not able to find a single
study that tested the effect of rhGH and/or aromatase inhi-
bitors starting during the latest stage of puberty in adoles-
cents with ISS.
Assessment of Benefit and Cost
Using adult height as a gold-standard outcome in growth
studies, the current observation suggests that combination
of rhGH and A allows for an additional mean height gain
of 4.9 cm versus rhGH alone, with a large variability of in-
dividual responses. The main predictor of height gain was
the duration of treatment, which was longer by 7.5 months
in the rhGH+A group. The other predictors of height
gain were the knee score, not the largely used hand bone
age, and the remaining growth velocity at rhGH onset.
A weakness of our trial is the lack of a true control
group. We could only compare the adult heights of ourpatients with PAH calculated by an equation especially
designed for near-ending and decelerating growth. Since
this equation proved capable of predicting adult height
accurately in historical controls, we felt comfortable to
use it for the treated patients. We found that rhGH
allowed a height gain close to 6 cm versus PAH, and that
addition of A to rhGH may have increased this gain up to
10.5 cm in average. Comparison with non-randomized
controls suggests a gain in final adult height of 4 cm with
rhGH alone and 8.3 cm with rhGH+A. In summary, the
rhGH+A treatment seems capable of increasing the adult
height of adolescent boys with ISS by 8–10 cm. We stress
however that the latter values should only be considered
indicative until randomized controlled trials in ISS ado-
lescents allow a more reliable estimation of the height
gain improvement.
The optimal dose and duration of rhGH treatment are
debated in children with ISS. The impression is that des-
pite the significant gain in height, many rhGH-treated
children remain short as adults, in the lower level of the
normal range. This may simply be that most studies have
used rhGH doses of 0.16 to 0.26 mg/kg/week, which may
not have been adequate [41]. Several dose–response
studies in prepubertal children with ISS have explored a
wide range of rhGH doses from 0.20-1.75 mg/kg/week
[2,12,17,38-40,43,50-52,77]. The benefit obtained seems
dose dependent and mean benefits of 7–8 cm for adult
height have been reported with doses of 0.32 to 0.4 mg/
kg/week [11,12,17] consistently with a recent report
from the US [41]. Given that the treatment duration
was expected to be short in our trial, we selected a
rhGH dose around 0.5 mg/kg/week then guided therapy
using growth velocity and IGF1 levels. The total rhGH
dose delivered to the adolescents with ISS was 21 mg/kg
in the rhGH group and 35 mg/kg in the rhGH+A group,
respectively. Although given at a higher weekly dosage,
these cumulative doses represent only 23% and 38% of the
91 mg/kg totaled by the majority of children with ISS who
are treated with a traditionally recommended dose of
0.05 mg/kg.d for an average of 5.4 yrs [2]. Although this is
yet speculative, it is thus possible that our regimen of
IGF1-based rhGH dosing may offer a dose-sparing and
safer mode of therapy, as discussed by Chen and al [51].
Clearly however, it would be premature to draw conclusions
from such a small number of children on trial, who are
being presented here to stimulate the study of new rhGH
regimens for short stature. The intention of our trial was
initially to find a mean to rescue short stature at a time of
near finished growth. Notably, our approach of rhGH+A
administration at the end of puberty cannot be extrapolated
to a large proportion of children with ISS before compari-
son is performed with the traditional prolonged rhGH
treatment at lower classical doses starting at younger ages
through larger trials.
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chase of rhGH from distributing pharmacies, may be as
much as $88,000 to $100,000 per gram in the USA [41].
If our observations are confirmed in larger series of adoles-
cents with ISS, they might contribute to design a cheaper
treatment of ISS without compromising height gain. The
estimated cost of rhGH therapy compared with no therapy,
in 2011, was $47,000 or more per cm [72], depending on
unit cost and height gain. If our results were confirmed,
the 8–10 cm gain would translate into a cost of $18,000
per cm in the rhGH+A (vs untreated subjects) group,
where no treated subject gained less than 4 cm.
We have not evaluated the effect of the treatment or of
perceived height gain on the quality of life (QOL) of the
participants. Not unexpectedly, all adolescents faced with
a small height simply enjoyed the gain of extra height, and
regretted only that the gain could not be greater. Our per-
sonal opinion is that QOL questionnaires and method-
ology are not specific enough to reflect people’s thoughts
about their height accurately.
Safety issues
Concerns over long-term safety of rhGH have been re-
cently revisited [81-84]. As summarized, rhGH has “an en-
viable track record of safety” [83]. Recent results have been
reassuring [81,85]. The current trial being maybe the short-
est in duration of published studies, safety issues were only
limited to short term tolerance.
The utilization and safety of aromatase inhibitors in male
subjects were recently reviewed [86]. Lowering estradiol
levels within the male physiological range is associated with
an increase in levels of LH, FSH and testosterone [87,88],
as observed in the current study and found to be reversible
with cessation of treatment. When treated with letrozole at
the beginning of puberty, boys showed lower IGF1 levels
than controls [89], an observation that was not repli-
cated here under rhGH treatment. As reported [90],
we observed a slight and reversible decrease in HDL-
cholesterol, but none of the lipid values recorded during
A administration could be considered even borderline-
abnormal [91]. Letrozole-treated boys with ISS showed no
loss of bone density [92,93], but some mild vertebral de-
formities were observed in prepubertal boys with ISS or a
delayed onset of puberty treated with letrozole for 2 years
[71,93]; we screened but did not observe any vertebral de-
formities in the studied adolescents. Again, the short dur-
ation of our trial does not allow us to draw any conclusion
for mid or long term safety, and off label use of aromatase
inhibitors for the treatment of short stature is currently
not recommended outside a research setting.
Conclusion
If the current results are confirmed, starting treatment
of boys with ISS in late adolescence may have severaladvantages over the classical regimen of rhGH adminis-
tration to healthy children predicted to be adults of very
short stature. First, it allows more mature adolescents to
participate in the decision of attempting rhGH treatment,
a clear ethical advantage over treating children unable to
participate to the decision. Secondly, the advanced epi-
physeal fusion and near-ending growth trajectory allow a
more accurate prediction of adult height than when it is
attempted in earlier ages. Also, the shorter duration of ad-
ministration may have a cost/benefit advantage.
In summary, a short administration of rhGH and A
seems able to increase adult height in adolescents with
ISS in their late stage of puberty, more than does rhGH
alone, provided that epiphyseal plates are not completely
fused at the knee and growth velocity is still significant
at time of starting rhGH administration. However, be-
cause of the small size of the current trial, the lack of
randomization versus untreated short adolescents and
the short-term surveillance, we cannot recommend this
off label treatment, which should remain in a clinical re-
search setting. Larger RCTs will be needed to establish the
cost/benefit ratio of rhGH and A administration when
attempted in the late period of pubertal growth.
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